Tofacitinib (Xeljanz): Nursing Drug Guide, Serious Infections & NCLEX Review
Oral JAK inhibition suppresses cytokine signaling but carries a boxed warning for serious infections (including TB), malignancy, increased mortality, major adverse cardiovascular events, and thrombosis—especially versus TNF blockers in older RA patients. Nurses screen for infection and cytopenias before every dose, interrupt therapy when infection is serious, and never give live vaccines concurrently.
XELJANZ increases risk of serious bacterial, fungal, viral, and opportunistic infections—including tuberculosis (TB)—that may lead to hospitalization or death. Interrupt XELJANZ/XELJANZ XR if a serious infection occurs until the infection is controlled. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, including those with an initial negative latent TB test. The boxed warning also notes higher all-cause mortality, malignancy (including lymphoma and lung cancer versus TNF blockers in RA), major adverse cardiovascular events, and thrombosis (including pulmonary embolism). Avoid use during active serious infection, including localized infections. Document infection screening, lab holds, thrombosis symptom teaching, and prescriber notification.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every Xeljanz dose, confirm no active infection, review infection symptoms and TB risk, check whether CBC thresholds require a hold, and verify no live vaccine is due today. Interrupt therapy for serious infection until controlled; do not start when lymphocytes are below 500 cells/mm3, ANC is below 1000 cells/mm3, or hemoglobin is below 9 g/dL per labeling.
Most common brand names
Xeljanz is the brand name for tofacitinib, a Janus kinase (JAK) inhibitor given by mouth as immediate-release tablets, extended-release tablets (XELJANZ XR), or oral solution. XELJANZ XR is not substitutable with XELJANZ tablets or oral solution—formulation switches require prescriber direction.
Strengths include 5 mg and 10 mg tablets, 11 mg and 22 mg XR tablets, and 1 mg/mL oral solution for pediatric weight-based dosing. Patients often take methotrexate or corticosteroids concurrently; most serious infections in trials occurred with additional immunosuppressants per labeling. Do not combine duplicate JAK inhibitors or overlapping biologic DMARD orders on one MAR.
Why we give it — Indications
Tofacitinib is indicated for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; pediatric PsA and polyarticular JIA; and adults with moderately to severely active ulcerative colitis per XELJANZ labeling. Nurses in rheumatology, gastroenterology, and specialty clinics focus on infection/TB screening, lab monitoring for cytopenias, thrombosis symptom vigilance, and oral adherence.
| Use | Detail |
|---|---|
| Rheumatoid / psoriatic arthritis & ankylosing spondylitis | Adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, or active ankylosing spondylitis. Maintenance: XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily when labs permit. XELJANZ 10 mg twice daily and XELJANZ XR 22 mg once daily are not recommended for RA, PsA, AS, or pcJIA per labeling. |
| Ulcerative colitis & pediatric PsA / pcJIA | Adults with moderately to severely active ulcerative colitis (induction then maintenance per Table 3). Pediatric patients ≥2 years with PsA or polyarticular course JIA use weight-based tablet or oral solution dosing. Monitor fever, abdominal symptoms (GI perforation risk), and infection throughout therapy. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Tofacitinib is a Janus kinase (JAK) inhibitor that modulates intracellular signaling of cytokines important in lymphocyte function by inhibiting JAK enzymes. Reduced JAK signaling decreases inflammatory activity in RA, PsA, AS, UC, and JIA, but also impairs host defense against TB, herpes viruses, fungi, and other pathogens. Nurses therefore prioritize infection and TB screening, CBC monitoring, thrombosis symptom assessment, and hold rules before focusing on whether the patient swallowed the correct tablet strength.
Dosing overview
Dosing is indication-specific and depends on formulation (tablet, XR, oral solution), renal/hepatic function, and interacting drugs. Verify orders against current XELJANZ prescribing information Tables 1–4 and institutional protocol.
Missed dose: Not specified in the reviewed prescribing information. Follow prescriber orders and institutional protocol; do not double doses unless specifically ordered.
Lab-based holds: Discontinue if lymphocytes <500 cells/mm3 or ANC <500 cells/mm3; interrupt if ANC 500–1000 cells/mm3 until ANC >1000; interrupt if hemoglobin <8 g/dL or drops >2 g/dL until normalized per Tables 1–4.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset | Not specified in the reviewed prescribing information for symptom onset timing | Clinical improvement may take weeks; do not assume lack of effect in the first few doses alone |
| Peak (tablets/solution) | Tmax 0.5–1 hour after oral dose; XR Tmax ~4 hours per labeling | Rapid absorption—verify correct formulation (immediate vs XR) on MAR |
| Half-life | ~3 hours (tablets/solution); XR ~6–8 hours | Shorter half-life than biologics; pharmacodynamic effects on CRP may persist >2 weeks after stop per labeling |
| Steady state | 24–48 hours with twice-daily tablets; ~48 hours with once-daily XR; negligible accumulation | Infection and thrombosis vigilance continues for entire treatment course |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm no active serious infection (including localized infection)—avoid XELJANZ during active infection per labeling
- Latent tuberculosis evaluation and treatment when indicated (QuantiFERON-TB Gold or equivalent); monitor for active TB during therapy even if initial test negative
- CBC: do not start if lymphocytes <500 cells/mm3, ANC <1000 cells/mm3, or hemoglobin <9 g/dL; baseline hepatic function; viral hepatitis screen per guidelines; update immunizations before start
- Review cardiovascular risk, smoking, thrombosis history, concomitant immunosuppressants, CYP3A4/CYP2C19 inhibitors, and duplicate JAK or biologic orders
Contraindications
- Labeling lists none as formal contraindications—clinical holds still apply for active infection, severe hepatic impairment (use not recommended), and lab thresholds above
- Serious hypersensitivity (angioedema, urticaria)—discontinue and evaluate per labeling
- Live vaccines concurrently; XELJANZ XR in patients with severe GI narrowing (non-deformable XR risk) per labeling
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Strong/moderate CYP3A4 or CYP2C19 inhibitors | Increased tofacitinib exposure—labeling requires dose reduction to 5 mg once daily for many inhibitor combinations in RA/PsA/AS | Verify pharmacy interaction check; hold and clarify if MAR still shows standard BID dose with new inhibitor |
| Live vaccines | Increased risk of vaccine-related infection on immunosuppression | Avoid live vaccines; update inactivated immunizations before start per guidelines; document vaccine type |
| Infliximab / other biologic DMARDs | Overlapping immunosuppression increases infection risk; duplicate pathway therapy is unsafe | Hold and clarify duplicate biologic or second JAK inhibitor on MAR; notify prescriber same day |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral—immediate-release tablet, extended-release tablet (swallow whole; do not crush, split, or chew XR), or oral solution with supplied syringe for pediatrics. May take with or without food per labeling.
- Verify formulation on MAR: XELJANZ tablets are not substitutable with XELJANZ XR—switching requires prescriber direction
- Match tablet strength (5 mg vs 10 mg) and XR strength (11 mg vs 22 mg) to indication; RA/PsA/AS should not use 10 mg BID or 22 mg XR daily per labeling
- Oral solution: use press-in adapter and dosing syringe per Instructions for Use; teach caregivers measurement technique
Even when the dose is prepared in the cup, do not administer if the patient reports fever, productive cough, dysuria, spreading cellulitis, or oral thrush until the prescriber reassesses. Labeling directs interrupting therapy until serious infection is controlled.
Expected therapeutic response
- Reduced joint swelling, pain, and morning stiffness in arthritis indications over weeks to months
- Decreasing CRP/ESR and improved functional scores when therapy is effective (lab trends vary by setting)
- GI symptom improvement in IBD and skin clearance in psoriasis—lack of response by labeled timeframes may prompt prescriber to discontinue (e.g., UC remission assessed by eight weeks in adults)
Red flags — Stop and act
Any new infection symptom on tofacitinib may represent serious or disseminated disease. Escalate early rather than treating fever alone at home.
- Persistent fever, chills, night sweats, or weight loss—consider TB reactivation or opportunistic infection
- New cough, hemoptysis, dyspnea, or chest pain—pulmonary or disseminated infection including TB
- Signs of sepsis (hypotension, tachycardia, altered mental status, rigors) or invasive fungal infection in endemic regions
- Anaphylaxis, angioedema, or widespread rash—stop Xeljanz and treat allergic emergency per labeling
- Sudden chest pain, unilateral leg swelling, acute dyspnea, or hemoptysis—evaluate for pulmonary embolism or thrombosis; discontinue per labeling
- New severe abdominal pain (GI perforation risk, especially with NSAIDs or diverticulitis history); HBV reactivation; cytopenia symptoms (bleeding, recurrent infection, severe fatigue)
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Upper respiratory infection / nasopharyngitis / UTI | Common infections in RA trials (~4%, 3%, 2% of patients respectively in labeling) | Differentiate mild viral illness from serious infection; hold and escalate if systemic or persistent |
| Headache, diarrhea, hypertension | Common adverse reactions in labeling | Monitor; evaluate whether symptoms reflect infection, thrombosis, or GI perforation |
| Serious infections (TB, herpes zoster, fungal, sepsis) | Boxed warning; may be fatal | Interrupt XELJANZ until controlled; ID evaluation; sepsis protocol when indicated |
| MACE, thrombosis, malignancy | Boxed warning; higher rates versus TNF blockers in RA safety study | Report chest pain, dyspnea, leg swelling, neurologic deficits; smoking cessation support; prescriber risk-benefit review |
| Lymphopenia, neutropenia, anemia, elevated lipids/LFTs | Labeled lab abnormalities with dose-interruption rules | Trend CBC and liver function tests; hold per Tables 1–4 when thresholds met |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
There is no specific antidote for overdose with XELJANZ tablets, oral solution, or XELJANZ XR per labeling.
Overdose management
- Monitor for signs and symptoms of adverse reactions after supratherapeutic exposure
- Hemodialysis removes only a small fraction of drug due to significant non-renal clearance—limited value for overdose removal per labeling
- Contact local poison control or medical toxicology services per facility protocol and local emergency guidance
Look-alike / sound-alike and error prevention
- XELJANZ vs XELJANZ XR—not substitutable; verify formulation on every administration
- 5 mg vs 10 mg tablets and 11 mg vs 22 mg XR—RA/PsA/AS should not receive 10 mg BID or 22 mg XR per labeling
- Xeljanz vs other JAK inhibitors (baricitinib, upadacitinib)—class confusion on MAR after formulary changes
- Duplicate immunosuppression—MAR may list tofacitinib plus biologic DMARD; hold and clarify
- Live vs inactivated vaccines—document vaccine type explicitly when coordinating with primary care
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Do not crush, split, or chew XELJANZ XR; tablets may be split only if prescriber/pharmacy directs per institutional policy |
| Food timing | May take with or without food per labeling |
| Storage | Store per product labeling and Instructions for Use; protect oral solution adapter/syringe from contamination |
| Formulation checks | Confirm immediate-release vs XR on MAR; switching 5 mg BID to 11 mg XR occurs day after last 5 mg dose per labeling |
| Missed dose | Not specified in the reviewed prescribing information—follow prescriber and institutional protocol |
| Commonly missed | Continuing BID dosing when CBC shows ANC 600 cells/mm3; giving live nasal flu vaccine; ignoring pleuritic chest pain on therapy |
| Ask pharmacy when | New CYP inhibitor added, renal function change on dialysis, or hold/resume after serious infection |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| RA patients ≥50 years with cardiovascular risk factors | Postmarketing RA safety study showed higher mortality, MACE, thrombosis, and malignancy with XELJANZ versus TNF blockers—use lowest effective dose; avoid 10 mg BID in RA/PsA/AS per labeling |
| TB exposure, endemic mycoses regions, or chronic/recurrent infection history | Evaluate TB risk factors before and during therapy; consider empiric antifungal evaluation if systemic illness occurs in histoplasmosis/coccidioidomycosis regions |
| HBV carriers and heart failure | Monitor HBV carriers for reactivation during and months after therapy; use caution in heart failure and watch for worsening symptoms per labeling |
| Pregnancy | Available human pregnancy registry and published data are insufficient to establish drug-associated risk of major birth defects or miscarriage per labeling; increased disease activity in RA/UC can harm pregnancy outcomes. Use only if clearly needed after risk/benefit discussion with prescriber. |
| Lactation | Tofacitinib is present in human milk; limited infant data with no reported adverse effects in small case series per labeling. Because of serious infection risk on therapy, breastfeeding is not recommended during treatment and for at least 18 hours after last XELJANZ dose or 36 hours after last XELJANZ XR dose. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Infection symptoms at every contact: temperature, cough, dysuria, wound appearance, oral/thrush lesions, travel history
- TB screening per protocol when starting and periodically during therapy; HBV monitoring in carriers; CBC if symptoms of cytopenia
- CBC per labeling intervals; lipids 4–8 weeks after start; LFTs; infection and thrombosis symptoms; therapeutic response (joints, GI, function)
Document
- Formulation (tablet vs XR vs solution), dose (mg), time given, and patient tolerance
- Pre-therapy TB screen, vaccines deferred, lab holds, prescriber notification for suspected infection or thrombosis
- Patient teaching on fever reporting, live-vaccine avoidance, when to seek emergency care, and missed-dose instructions
Patient teaching
- Report fever, persistent cough, night sweats, weight loss, painful urination, leg swelling, chest pain, or sudden shortness of breath immediately—do not take the next dose until the care team clears you
- Avoid live vaccines during therapy; ask the team before any vaccine and before travel to fungal-endemic regions
- Take the correct tablet or liquid dose at the scheduled times—do not switch between immediate-release and XR without prescriber instruction
- Missed-dose instructions: follow prescriber and pharmacy guidance (not specified in the reviewed prescribing information)
- Inform dentists, surgeons, and emergency staff that you take a JAK inhibitor that increases infection risk
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Active serious infection or new systemic infection symptoms until prescriber reassesses—interrupt per labeling until infection controlled
- Latent TB untreated when positive, or suspected TB reactivation
- CBC thresholds: lymphocytes <500 cells/mm3, ANC <1000 cells/mm3 at start, ANC 500–1000 cells/mm3, hemoglobin <8 g/dL or drop >2 g/dL on therapy
- Scheduled live vaccine; duplicate JAK inhibitor or biologic on MAR; new thrombosis symptoms; serious hypersensitivity
- Wrong formulation (XR vs tablet), RA/PsA/AS order for 10 mg BID or 22 mg XR when not indicated, or expired product
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Rheumatology and gastroenterology nurses gatekeep oral JAK therapy with the same infection rigor as injectable biologics—plus CBC thresholds, thrombosis symptom checks, and formulation verification (tablet vs XR).
1. Check-before-you-give protocol
- Right patient, drug, formulation (tablet/XR/solution), dose (mg), schedule, and indication
- Screen for infection and thrombosis symptoms; review recent CBC and whether lab holds apply
- Verify no duplicate JAK inhibitor or biologic DMARD; check new CYP inhibitors on MAR
- Confirm no live vaccine today; match 5 mg BID vs 11 mg XR to prescriber order
2. High-alert and safety badge
Not on standard high-alert medication lists, but carries boxed warnings for serious infection, mortality, malignancy, MACE, and thrombosisTreat Xeljanz with immunosuppressant-level safety: infection/TB screen, lab holds, thrombosis teaching, and independent double-check of formulation—even for oral self-administration.
3. Clinical workflow: hold and question rules
- Fever or infection symptoms: hold dose, notify prescriber same day, initiate infection workup per protocol
- ANC 500–1000 cells/mm3 or hemoglobin below labeled thresholds: interrupt dosing until values normalize per Tables 1–4
- Serious infection or sepsis: interrupt XELJANZ until controlled; do not resume until prescriber and ID agree
4. Critical teach-back questions
- “What symptoms should you report before your next dose?” (Patient should name fever, night sweats, cough, leg swelling, chest pain, shortness of breath, painful urination—and state they will call before taking the dose.)
- “Can you take live vaccines while on Xeljanz?” (Patient should say live vaccines should be avoided during therapy and they will confirm vaccine type with the prescriber or pharmacist before any immunization.)
5. Care coordination
Prescriber (rheumatology / gastroenterology): Confirm indication-specific dose, RA/PsA/AS avoidance of 10 mg BID, UC lowest effective dose, and hold/resume after infection
Pharmacist / infectious disease: TB interpretation, CYP interaction dose changes, CBC monitoring intervals, and thrombosis risk counseling
🧠 Quick mental checklist
- Active infection or new fever, cough, dysuria, or night sweats?
- Latent TB treated before start—and ongoing TB monitoring?
- CBC OK to give (lymphocytes, ANC, hemoglobin per labeling)?
- Correct formulation and dose—not 10 mg BID for RA without prescriber intent?
- Thrombosis symptoms or live vaccine on today’s plan?
Tofacitinib NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for Xeljanz serious-infection and lab-hold safety: use the tabbed case panel (MAR, labs, I&O/vitals, nursing notes), then priority action, SATA cue recognition, lab trend interpretation, hold-documentation cloze, ordered escalation, and matrix urgency—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O/vitals, and nursing note details for this case.
- Xeljanz (tofacitinib) 5 mg PO twice daily — 0900 dose held pending assessment
- Methotrexate 15 mg PO weekly — taken last Saturday per patient report
- Atorvastatin 20 mg PO nightly — taken last night
- Pharmacy note: XELJANZ 5 mg tablet (not XR) verified; no second JAK or biologic on MAR
- CBC today: WBC 6.8 ×109/L; Hgb 11.4 g/dL (was 13.1 one month ago); platelets 210 ×109/L
- ANC 1.4 ×109/L; lymphocytes 0.9 ×109/L (520 cells/mm3 last month)
- CRP 42 mg/L (was 18); ESR 48 mm/hr
- QuantiFERON-TB Gold negative 4 months ago (pre-start); repeat ordered — pending
- 58-year-old with rheumatoid arthritis; current smoker (10 cigarettes/day); hypertension
- Today 0900: temp 38.4 °C; HR 104; BP 128/76; RR 20; SpO2 94% on room air
- Productive cough × 5 days; night sweats; 2-kg weight loss; denies pleuritic chest pain now
- CXR and sputum culture ordered; blood cultures drawn
- 0845: Patient took morning Xeljanz at home before arrival—nurse instructed to hold further doses
- 0900: Notified rheumatology NP; infection pathway initiated; patient educated on hold
- 0910: Patient asks whether to take tonight’s 5 mg dose if cultures are still pending
- Teaching due: fever, cough, hemoptysis, leg swelling, chest pain—call before any dose
Answer key & rationale
Frequently asked questions
When should a nurse hold Xeljanz and call the prescriber?
Hold when there is active or suspected serious infection, untreated latent TB, CBC below labeling thresholds, scheduled live vaccines, thrombosis symptoms, duplicate JAK/biologic therapy, or serious hypersensitivity. XELJANZ labeling directs avoiding use during active serious infection and interrupting therapy until serious infection is controlled.
What TB screening does Xeljanz labeling require?
Evaluate and test for latent or active TB before and during therapy per applicable guidelines. Treat latent TB before starting XELJANZ when indicated. Monitor all patients for active TB during treatment even when initial latent testing is negative.
What labs should nurses track on tofacitinib?
Labeling recommends CBC monitoring (lymphocytes at baseline and every 3 months; neutrophils and hemoglobin at baseline, 4 to 8 weeks, then every 3 months), routine liver tests, lipid assessment 4 to 8 weeks after start, plus infection and TB surveillance per protocol.
Can patients receive live vaccines on Xeljanz?
Avoid live vaccines concurrently with XELJANZ or XELJANZ XR. Update immunizations per current guidelines before starting therapy, with interval between live vaccination and initiation per immunosuppressive-agent guidance.
Is there an antidote for Xeljanz overdose?
No specific antidote is listed in the reviewed prescribing information. Monitor for adverse reactions; hemodialysis has limited removal value. Contact local poison control or medical toxicology services per facility protocol and local emergency guidance.
Why is 10 mg twice daily restricted in rheumatoid arthritis?
In RA patients ≥50 years with cardiovascular risk factors, postmarketing data showed higher mortality, MACE, thrombosis, and malignancy with XELJANZ 10 mg twice daily versus 5 mg twice daily or TNF blockers. XELJANZ 10 mg twice daily and XELJANZ XR 22 mg once daily are not recommended for RA, PsA, AS, or pcJIA per labeling.
References
-
U.S. National Library of Medicine. XELJANZ (tofacitinib) tablets, XELJANZ XR, and oral solution — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13
-
U.S. Food and Drug Administration. XELJANZ / XELJANZ XR (tofacitinib) prescribing information label PDF (revised March 2026).https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208246s027lbl.pdf
-
U.S. Food and Drug Administration. FDA Drug Safety Communication — Update on safety review of tofacitinib (Xeljanz).https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-update-safety-review-tofacitinib
-
Centers for Disease Control and Prevention. Tuberculosis (TB) — Clinical testing and diagnosis.https://www.cdc.gov/tb/hcp/testing-diagnosis/index.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.